Fesoterodine

Drugs

Volumn 69, Issue 6, 2009, Pages 731-738

  McKeage, Kate ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLTOLTERODINE; ATROPINE; CLARITHROMYCIN; DRUG METABOLITE; FESOTERODINE; ITRACONAZOLE; KETOCONAZOLE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; TOLTERODINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; FOOD DRUG INTERACTION; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OVERACTIVE BLADDER; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESIDUAL URINE; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; HUMANS; MUSCARINIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 65949119119     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969060-00006     Document Type: Review

References (20)

1. Staskin DR, MacDiarmid SA. Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 2006 Mar; 119 (3 Suppl. 1): 24-8.
2. Irwin D, Milsom I, Reilly K, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306-15.
3. De Groat WC. Aneurologic basis for the overactive bladder. Urology 1997; 50 Suppl. 6A: 36-52.
4. Dmochowski R. Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf 2005; 28 (7): 583-600.
5. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9 (10): 1787-96.
6. Pfizer Labs. Toviaz- (fesoterodine fumarate) extended release tablets: prescribing information [online]. Available from URL: http://media.pfizer.com/ files/products/uspi-toviaz.pdf [Accessed 2008 Dec 1].
7. European Medicines Agency. Toviaz 4mg prolonged-release tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/toviaz/H-723-PI-en.pdf [Accessed 2008 Nov 27].
8. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008; 101 (8): 1036-42.
9. Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005; 144 (8): 1089-99.
10. Malhotra B, Wood N, Holbrook M, et al. Thorough QT study to evaluate the effect of fesoterodine on cardiac repolarization [abstract no. P052]. Fundam Clin Pharmacol 2008; 22 (Suppl. 2): 68.
11. Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46 (11): 556-63.
12. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178 (6): 2488-94.
13. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52 (4): 1204-12.
14. Chapple C. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study [abstract no. 142 plus poster]. 34th Annual Meeting of the International Continence Society; 2004 Aug 23-27; Paris.
15. Nitti V, Wiatrak M, Kreitman L, et al. Fesoterodine is an effective antimuscarinic for patients with overactive bladder: results of a phase 2 trial [abstract no. 306 plus poster]. 35th Annual Meeting of the International Continence Society; 2005 Aug 31-Sep 2; Montreal (QC).
16. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102 (1): 56-61.
17. Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008; 72 (4): 803-7.
18. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008; 71 (5): 839-43.
19. Chapple CR, Van Kerrebroeck PE, Jü nemann K-P, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008; 102 (9): 1128-32.
20. Data on file, Pfizer, 2009.